JP2012511588A5 - - Google Patents

Download PDF

Info

Publication number
JP2012511588A5
JP2012511588A5 JP2011540890A JP2011540890A JP2012511588A5 JP 2012511588 A5 JP2012511588 A5 JP 2012511588A5 JP 2011540890 A JP2011540890 A JP 2011540890A JP 2011540890 A JP2011540890 A JP 2011540890A JP 2012511588 A5 JP2012511588 A5 JP 2012511588A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
hydrogen
alkoxy
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011540890A
Other languages
English (en)
Japanese (ja)
Other versions
JP5669749B2 (ja
JP2012511588A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/067507 external-priority patent/WO2010068761A2/en
Publication of JP2012511588A publication Critical patent/JP2012511588A/ja
Publication of JP2012511588A5 publication Critical patent/JP2012511588A5/ja
Application granted granted Critical
Publication of JP5669749B2 publication Critical patent/JP5669749B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011540890A 2008-12-10 2009-12-10 ウイルス複製の阻害剤である4−アミノ−4−オキソブタノイルペプチド環状類似体 Expired - Fee Related JP5669749B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12137808P 2008-12-10 2008-12-10
US61/121,378 2008-12-10
US22632309P 2009-07-17 2009-07-17
US61/226,323 2009-07-17
PCT/US2009/067507 WO2010068761A2 (en) 2008-12-10 2009-12-10 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication

Publications (3)

Publication Number Publication Date
JP2012511588A JP2012511588A (ja) 2012-05-24
JP2012511588A5 true JP2012511588A5 (enExample) 2012-11-22
JP5669749B2 JP5669749B2 (ja) 2015-02-12

Family

ID=42241240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540890A Expired - Fee Related JP5669749B2 (ja) 2008-12-10 2009-12-10 ウイルス複製の阻害剤である4−アミノ−4−オキソブタノイルペプチド環状類似体

Country Status (14)

Country Link
US (2) US20100152103A1 (enExample)
EP (1) EP2364310B1 (enExample)
JP (1) JP5669749B2 (enExample)
KR (1) KR20110096557A (enExample)
CN (1) CN102245598B (enExample)
AU (1) AU2009324644B2 (enExample)
BR (1) BRPI0922913A2 (enExample)
CA (1) CA2746265A1 (enExample)
EA (1) EA021794B1 (enExample)
IL (1) IL212787A0 (enExample)
MX (1) MX2011006239A (enExample)
NZ (1) NZ592705A (enExample)
WO (1) WO2010068761A2 (enExample)
ZA (1) ZA201104383B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009142842A2 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
AU2009303483A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8835456B1 (en) 2011-03-18 2014-09-16 Achillion Pharmaceuticals, Inc. NS5A inhibitors useful for treating HCV
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PH12013502455A1 (en) 2011-05-27 2014-01-20 Achillion Pharmaceuticals Inc Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
HRP20161694T1 (hr) 2012-10-19 2017-03-10 Bristol-Myers Squibb Company 9-metil supstituirani heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4) diazaciklopentadecinil karbamat derivati kao ne-strukturalni 3 (ns3) proteazni inhibitori za liječenje infekcija virusom hepatitisa c
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG11201508431VA (en) 2013-03-13 2015-11-27 Harvard College Stapled and stitched polypeptides and uses thereof
US9085607B2 (en) * 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
CA2909270A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv
EP3008081B1 (en) 2013-06-14 2017-08-30 President and Fellows of Harvard College Stabilized polypeptide insulin receptor modulators
US10533039B2 (en) 2014-05-21 2020-01-14 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
MX2020002435A (es) 2017-09-07 2020-09-22 Fog Pharmaceuticals Inc Agentes que modulan las funciones de beta-catenina y sus métodos.

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
CN100391967C (zh) * 2000-11-20 2008-06-04 布里斯托尔-迈尔斯斯奎布公司 丙型肝炎三肽抑制剂
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
WO2004043339A2 (en) * 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
US20060199773A1 (en) * 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
DE60336550D1 (de) * 2002-05-20 2011-05-12 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
WO2004072243A2 (en) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
CA2516018C (en) * 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP4914355B2 (ja) * 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎インヒビターペプチド類似体
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CN101039947A (zh) * 2004-08-09 2007-09-19 布里斯托尔-迈尔斯斯奎布公司 Hcv复制抑制剂
US7659263B2 (en) * 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2041156B1 (en) * 2006-07-13 2013-11-20 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
WO2010068760A2 (en) * 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication

Similar Documents

Publication Publication Date Title
JP2012511588A5 (enExample)
JP2014506599A5 (enExample)
JP2010536887A5 (enExample)
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
JP2014525432A5 (enExample)
JP2017538722A5 (enExample)
JP2019536785A5 (enExample)
JP2013507425A5 (enExample)
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
JP2009529047A5 (enExample)
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
HRP20192274T1 (hr) Novi derivati oktahidro-pirolo[3,4−c]-pirola i njihovi analozi kao inhibitori autotaksina
JP2018519323A5 (enExample)
RU2010117156A (ru) Гетероциклические соединения в качестве антагонистов crth2 рецептора
JP2016525075A5 (enExample)
EA200901573A1 (ru) Гетероарилзамещенные тиазолы
CA2652834A1 (en) Substituted arylimidazolones and -triazolones and the use thereof
RU2005122901A (ru) Производные пиридино [2,3-] пиримидина в качестве селективных ингибиторов kdr и fgfr
NO20060670L (no) N3-substituerte imidazopyridin C-kit inhibitorer
JP2014514360A5 (enExample)
JP2010526800A5 (enExample)
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
EA201171000A1 (ru) Производные азаспиранилалкилкарбаматов в форме 5-членных гетероциклов, способ их получения и применение в терапии
JP2013510178A5 (enExample)